-- 江蘇ロパルテック(上海証券取引所:603906、香港証券取引所:2465)は、オーストラリアのリチウム探査権および関連資産を1,490万豪ドルで取得することで合意したと、火曜日に香港証券取引所に提出した書類で明らかにした。 自動車用特殊化学品販売会社である同社の株価は、水曜日の午前中の取引で1%以上上昇した。 同社はグローバル・リチウム・リソーシズとMBリチウムから鉱区を取得する。マーブルバー・リチウム鉱山プロジェクトを稼働させるには、今後2~3年間で2億ドル以上の投資が必要になると述べた。 ロパルテックは、この鉱山が上流資源、特にリン酸鉄リチウム正極材における戦略的基盤の強化に役立つと述べた。 一方、別の発表では、同社は原材料需要を支えるため、グローバル・リチウム・リソーシズおよびGLRオーストラリアと、購入、オフテイク、前払いに関する基本合意書を締結した。 本契約では、グローバル・リチウム・リソーシズ社の株式1,380万株(事業の5%に相当)を1株あたり0.52875豪ドルで引き受けること、マンナ・リチウム・プロジェクトにおけるスポジュメン精鉱の年間生産量の40%を供給すること、そして供給確保のためロパル・テック社が7,500万豪ドルを前払いすることが規定されている。 ロパル・テック社は、まず30日以内に750万豪ドルを前払いし、残りの6,750万豪ドルを4回の均等分割払いで支払う予定である。 ロパル・テック社は、この支払いスケジュールが同社の定期資金調達に「一定の圧力」をかける可能性があると述べている。 グローバル・リチウム・リソーシズ社は、2026年末までにマンナ・リチウム・プロジェクトへの最終投資決定を行う予定であり、2028年6月に出荷を開始する見込みである。
Related Articles
Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.
Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.
Research Alert: CFRA Maintains Hold Opinion In Shares Of Wab
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $285 from $275 following WAB's Q1 earnings print, valuing shares at 24.2x our 2027 EPS outlook of $11.76 (revised from $11.46; 2026 EPS estimate up to $10.57 from $10.50), a slight premium to WAB's long-term historical multiple average given structural improvements in earnings quality. While we are cautious on signs of overcapacity in the freight market, an elevated order backlog (12-month sits at over $9 billion), internal initiatives to shore up margins, and potential synergies from M&A activity positions WAB to continue growing earnings at double-digit rates in 2026-2027, in our view. Despite tariff-related cost pressures, WAB has done a commendable job of defending margins via a mix of pricing, lean manufacturing, and pruning of lower-profit operations. Q1 results were mixed but overall positive, in our view. We maintain our Hold recommendation on shares.